|
|
Post by centralcoastinvestor on Jul 7, 2018 13:37:24 GMT -5
I think it is safe to say that most long term shareholders are still concerned about the cash that Mnkd has for ongoing operations. The beaten down share price doesn’t make it easy to raise cash in the market. Thus the concern about dilution. Further, advertising is expensive but it ultimately will be the salvation of Afrezza and MannKind. So Mike C. and Mnkd management have had to walk a razor thin tight rope of preserving cash and spending on advertising.
So I have asked myself why the big push in advertising now? Some obvious answers come to mind:
1. With the ADA presentation still fresh in all of the Endo’s memories, now is the perfect time to get new people to ask their personal endocrinologists to try Afrezza.
2. It has been awhile since the test advertising campaign occurred and it was time to launch a bigger effort.
Both of these are sound reasons to make a big push now. However, with cash probably getting low, wouldn’t it have been better to raise cash first and then begin the advertising push? Unless there was another underlying reason for a big advertising push besides what is mentioned above. What if part of the criteria for getting higher end financing hinged on proof of the advertising concept? For instance, what if over the next four weeks Mnkd could show that for every million spent there was a specified return on that money that was trackable? Then perhaps Mnkd could obtain debt financing instead of dilution. Financial institutions would need some hard proof that their investment had a reasonable chance of being paid back. What if those metrics showed that in a certain reasonable timeframe, Mnkd becomes cash self sufficient? Makng the payoff of debt much more assured.
If significant debt financing could be secured with a payback out several years, the cash overhang issue would be resolved. Share price would inevitably go up making it far easier to raise money in the market. Instead of being in the cash death spiral we have been in, we end up being able to raise cash easily. So I am keeping my fingers crossed that scripts go up over the next couple of months. Because if they do, future financing may not be a problem.
|
|
|
|
Post by sportsrancho on Jul 7, 2018 14:55:48 GMT -5
Agree, all very good points.
I was told by someone you don’t have to pay for between 30 and 60 days for the commercials.
That being said, this is do or die, we need traction, we need to get as close to guidance as possible, we need to attract a partner IMO. We need to prove we can take market share to do that. I’m very happy about this I think they’re doing the right thing.
|
|
|
|
Post by golfeveryday on Jul 7, 2018 15:27:20 GMT -5
Agree, all very good points. I was told by someone you don’t have to pay for between 30 and 60 days for the commercials. That being said, this is do or die, we need traction, we need to get as close to guidance as possible, we need to attract a partner IMO. We need to prove we can take market share to do that. I’m very happy about this I think they’re doing the right thing. this whole traction thing is good conversation. We do need traction, no doubt, but plenty of companies partner way back in the clinical stage. MNKD proved Afrezza was promotionally sensitive last year. I recall them talking about it in one of their calls. They don’t have to prove it and they have new data as well. I would be shocked if they were not in late stage negotiations with a company post ADA data. My hope is MC and company don’t start to think they can do this alone. |
|
|
|
Post by peppy on Jul 7, 2018 16:51:50 GMT -5
I think it is safe to say that most long term shareholders are still concerned about the cash that Mnkd has for ongoing operations. The beaten down share price doesn’t make it easy to raise cash in the market. Thus the concern about dilution. Further, advertising is expensive but it ultimately will be the salvation of Afrezza and MannKind. So Mike C. and Mnkd management have had to walk a razor thin tight rope of preserving cash and spending on advertising. So I have asked myself why the big push in advertising now? Some obvious answers come to mind: 1. With the ADA presentation still fresh in all of the Endo’s memories, now is the perfect time to get new people to ask their personal endocrinologists to try Afrezza. 2. It has been awhile since the test advertising campaign occurred and it was time to launch a bigger effort. Both of these are sound reasons to make a big push now. However, with cash probably getting low, wouldn’t it have been better to raise cash first and then begin the advertising push? Unless there was another underlying reason for a big advertising push besides what is mentioned above. What if part of the criteria for getting higher end financing hinged on proof of the advertising concept? For instance, what if over the next four weeks Mnkd could show that for every million spent there was a specified return on that money that was trackable? Then perhaps Mnkd could obtain debt financing instead of dilution. Financial institutions would need some hard proof that their investment had a reasonable chance of being paid back. What if those metrics showed that in a certain reasonable timeframe, Mnkd becomes cash self sufficient? Makng the payoff of debt much more assured. If significant debt financing could be secured with a payback out several years, the cash overhang issue would be resolved. Share price would inevitably go up making it far easier to raise money in the market. Instead of being in the cash death spiral we have been in, we end up being able to raise cash easily. So I am keeping my fingers crossed that scripts go up over the next couple of months. Because if they do, future financing may not be a problem. This was a planned advertising push, outlined at the last MNKD conference call. |
|
|
|
Post by mnholdem on Jul 7, 2018 17:09:45 GMT -5
Logical strategy since it's much easier to get better terms on financing if a company is demonstrating sales growth vs shopping around in desperation.
I agree the mgt is also following up their ADA presentation, striking while the iron is still hot. But this must remain a sustained effort in order to build greater awareness and interest.
I'm looking forward to reading new publications. I think doctors want to know more. Well, fans, Kendall has left the on-deck circle and stepping up to the plate.
|
|
|
|
Post by mytakeonit on Jul 7, 2018 17:31:43 GMT -5
PLAY BALL !!!
|
|
|
|
Post by od on Jul 7, 2018 17:54:52 GMT -5
I think it is safe to say that most long term shareholders are still concerned about the cash that Mnkd has for ongoing operations. The beaten down share price doesn’t make it easy to raise cash in the market. Thus the concern about dilution. Further, advertising is expensive but it ultimately will be the salvation of Afrezza and MannKind. So Mike C. and Mnkd management have had to walk a razor thin tight rope of preserving cash and spending on advertising. So I have asked myself why the big push in advertising now? Some obvious answers come to mind: 1. With the ADA presentation still fresh in all of the Endo’s memories, now is the perfect time to get new people to ask their personal endocrinologists to try Afrezza. 2. It has been awhile since the test advertising campaign occurred and it was time to launch a bigger effort. Both of these are sound reasons to make a big push now. However, with cash probably getting low, wouldn’t it have been better to raise cash first and then begin the advertising push? Unless there was another underlying reason for a big advertising push besides what is mentioned above. What if part of the criteria for getting higher end financing hinged on proof of the advertising concept? For instance, what if over the next four weeks Mnkd could show that for every million spent there was a specified return on that money that was trackable? Then perhaps Mnkd could obtain debt financing instead of dilution. Financial institutions would need some hard proof that their investment had a reasonable chance of being paid back. What if those metrics showed that in a certain reasonable timeframe, Mnkd becomes cash self sufficient? Makng the payoff of debt much more assured. If significant debt financing could be secured with a payback out several years, the cash overhang issue would be resolved. Share price would inevitably go up making it far easier to raise money in the market. Instead of being in the cash death spiral we have been in, we end up being able to raise cash easily. So I am keeping my fingers crossed that scripts go up over the next couple of months. Because if they do, future financing may not be a problem. The pro-Afrezza data is probably getting attention as it circulates throughout the Endo community, but how many providers attended ADA? My understanding is that in recent years major Scientific Sessions have seen a significant decline in participants. That said, I don't disagree with your thinking. |
|
|
|
Post by babaoriley on Jul 7, 2018 18:42:28 GMT -5
Hi, CCI! I like your thoughts, however, the one "hope" of being able to obtain "significant debt financing," is, I believe, well out of our reach at any time in the near future - maybe at 1200-1500 scripts per week. Of course, there could be some convertible debt, but that's dilution, unless we're not successful, in which case, who cares. Another issue with financing is that so long as there is Deerfield debt, there is the question of priority, and a new lender, unless they take Deerfield's debt out, will likely subordinate to Deerfield's debt. As to the Mann entity, who knows what can be worked out there.
Is it as hot where you are as down here?
|
|
|
|
Post by golfeveryday on Jul 7, 2018 18:52:42 GMT -5
I think it is safe to say that most long term shareholders are still concerned about the cash that Mnkd has for ongoing operations. The beaten down share price doesn’t make it easy to raise cash in the market. Thus the concern about dilution. Further, advertising is expensive but it ultimately will be the salvation of Afrezza and MannKind. So Mike C. and Mnkd management have had to walk a razor thin tight rope of preserving cash and spending on advertising. So I have asked myself why the big push in advertising now? Some obvious answers come to mind: 1. With the ADA presentation still fresh in all of the Endo’s memories, now is the perfect time to get new people to ask their personal endocrinologists to try Afrezza. 2. It has been awhile since the test advertising campaign occurred and it was time to launch a bigger effort. Both of these are sound reasons to make a big push now. However, with cash probably getting low, wouldn’t it have been better to raise cash first and then begin the advertising push? Unless there was another underlying reason for a big advertising push besides what is mentioned above. What if part of the criteria for getting higher end financing hinged on proof of the advertising concept? For instance, what if over the next four weeks Mnkd could show that for every million spent there was a specified return on that money that was trackable? Then perhaps Mnkd could obtain debt financing instead of dilution. Financial institutions would need some hard proof that their investment had a reasonable chance of being paid back. What if those metrics showed that in a certain reasonable timeframe, Mnkd becomes cash self sufficient? Makng the payoff of debt much more assured. If significant debt financing could be secured with a payback out several years, the cash overhang issue would be resolved. Share price would inevitably go up making it far easier to raise money in the market. Instead of being in the cash death spiral we have been in, we end up being able to raise cash easily. So I am keeping my fingers crossed that scripts go up over the next couple of months. Because if they do, future financing may not be a problem. The pro-Afrezza data is probably getting attention as it circulates throughout the Endo community, but how many providers attended ADA? My understanding is that in recent years major Scientific Sessions have seen a significant decline in participants. That said, I don't disagree with your thinking. how well the ADA STAT data is making the rounds should be reflected in NRx’s very soon. |
|
|
|
Post by letitride on Jul 7, 2018 18:57:22 GMT -5
I believe Mike mentioned he wanted to get to 5000 scripts a week. Looks like he was serious. If he can move the needle from hundreds to thousands quick everything else is a non issue. Lets Ride!
|
|
|
|
Post by golfeveryday on Jul 7, 2018 19:05:43 GMT -5
I believe Mike mentioned he wanted to get to 5000 scripts a week. Looks like he was serious. If he can move the needle from hundreds to thousands quick everything else is a non issue. Lets Ride! what was break even? 2,000 per week? |
|
|
|
Post by letitride on Jul 7, 2018 19:32:43 GMT -5
I believe Mike mentioned he wanted to get to 5000 scripts a week. Looks like he was serious. If he can move the needle from hundreds to thousands quick everything else is a non issue. Lets Ride! what was break even? 2,000 per week? Like I said non issue! |
|
|
|
Post by mytakeonit on Jul 7, 2018 20:18:07 GMT -5
And the count of endos are  4,000 + Hmmm ... that means 1 or 2 each a week? |
|
|
|
Post by peppy on Jul 7, 2018 20:32:45 GMT -5
endo's need to start rubbing testosterone cream on their ______?
Hang Man.
Five letters
_ _ _ _ _
|
|
|
|
Post by rockstarrick on Jul 7, 2018 20:49:30 GMT -5
endo's need to start rubbing testosterone cream on their ______? Hang Man. Five letters _ _ _ _ _ 😂😂😂😂😂😂😂😂😂😂😂😂 |
|
4,000 + Hmmm ... that means 1 or 2 each a week? 